Top

Published in:

Open Access 01-08-2014 | Laboratory Investigation

The proteomic response in glioblastoma in young patients

Authors: Ruth F. Deighton, Thierry Le Bihan, Sarah F. Martin, Martin E. Barrios-Llerena, Alice M. J. Gerth, Lorraine E. Kerr, James McCulloch, Ian R. Whittle

Published in: Journal of Neuro-Oncology | Issue 1/2014

Abstract

Increasing age is an important prognostic variable in glioblastoma (GBM). We have defined the proteomic response in GBM samples from 7 young patients (mean age 36 years) compared to peritumoural-control samples from 10 young patients (mean age 32 years). 2-Dimensional-gel-electrophoresis, image analysis, and protein identification (LC/MS) were performed. 68 proteins were significantly altered in young GBM samples with 29 proteins upregulated and 39 proteins downregulated. Over 50 proteins are described as altered in GBM for the first time. In a parallel analysis in old GBM (mean age 67 years), an excellent correlation could be demonstrated between the proteomic profile in young GBM and that in old GBM patients (r² = 0.95) with only 5 proteins altered significantly (p < 0.01). The proteomic response in young GBM patients highlighted alterations in protein–protein interactions in the immunoproteosome, NFkB signalling, and mitochondrial function and the same systems participated in the responses in old GBM patients.

Available only for authorised users

Anderson E, Grant R, Lewis SC, Whittle IR (2008) Randomized phase III controlled trials of therapy in malignant glioma: Where are we after 40 years? Brit J Neurosurg 22:339–349CrossRef

Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumours stratified by patient age and tumor histological type: an analysis based in surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg 88:1–10PubMedCrossRef

Preusser M, de Ribaupierre S, Wöhrer A, Erridge SC, Hegi M, Weller M, Stupp R (2011) Current concepts and management of glioblastoma. Ann Neurol 70:9–21PubMedCrossRef

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef

Deighton RF, McGregor R, Kemp J, McCulloch J, Whittle IR (2010) Glioma pathophysiology: insights emerging from proteomics. Brain Path 20:691–703CrossRef

Lubec G, Krapfenbauer K, Fountoulakis M (2003) Proteomics in brain research: potentials and limitations. Prog Neurobiol 69:193–211PubMedCrossRef

Persson O, Brynnel U, Levander F, Widegren B, Salford LG, Krogh M (2009) Proteomic expression analysis and comparison of protein and mRNA expression profiles in human malignant gliomas. Proteomic Clin Appl 3:83–94CrossRef

MRC Brain Tumour Working Party (1990) Prognostic factors for high grade gliomas: development of a prognostic index. J Neurooncol 9:47CrossRef

Kleinschmidt-DeMasters Meltesen L, McGavran L, Lillehei KO (2006) Characterisation of glioblastomas in young adults. Brain Pathol 16:273–286PubMedCrossRef

10.

Latif AZ, Signorini D, Gregor A, Grant R, Ironside JW, Whittle IR (1998) Application of the MRC brain tumour prognostic index to patients with malignant glioma not managed in randomised control trial. J Neurol Neurosurg Psychiatry 64:747–750PubMedCentralPubMedCrossRef

11.

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981. Lancet Oncol 9:29–38PubMedCrossRef

12.

Lutterback J, Bartelt S, Momm F, Becker G, Frommhold H, Ostertag C (2005) Is older age associated with a worse prognosis due to different patterns of care? Cancer 103:1234–1244CrossRef

13.

Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Path 170:1445–1453PubMedCentralPubMedCrossRef

14.

Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, Passe S, Jenkins RB, Aldape KD (2002) Genetic aberrations defined by comparative genomic hybridization distinguish long-term typical survivors of glioblastoma. Cancer Res 62:6205–6210PubMed

15.

Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, Wiestler OD, Lois DN, Fimmers R, von Deeimling A (2002) Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropath Exp Neurol 61:321–328PubMed

16.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRef

17.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773PubMedCentralPubMedCrossRef

18.

Jansen M, Yip S, Louis DN (2010) Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 9:717–726PubMedCentralPubMedCrossRef

19.

Joshi AD, Parsons DW, Velculescu VE, Riggins GJ (2011) Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. Mol Cancer 10:17PubMedCentralPubMedCrossRef

20.

Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H et al. (2014) for the German Glioma Network. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer March 11 epub ahead of print

21.

Le Bihan T, Grima R, Martin S, Forster T, Le Bihan Y (2010) Quantitative analysis of low-abundance peptides in HeLa cell cytoplasm by targeted liquid chromatography/mass spectrometry and stable isotope dilution: emphasising the distinction between peptide detection and peptide identification. Rapid Commun Mass Spectrom 24:1093–1104PubMedCrossRef

22.

Cox J, Matic I, Hilger M, Nagaraj N, Selbach M, Olsen JV, Mann M (2009) A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat Protoc 4:698–705PubMedCrossRef

23.

Deighton RF, Kerr LE, Short DM, Allerhand M, Whittle IR, McCulloch J (2010) Network generation enhances interpretation of proteomic data from induced apoptosis. Proteomics 10:1307–1315PubMedCrossRef

24.

Santandreu FM, Brell M, Gene AH, Guevara R, Oliver J, Couce ME, Roca P (2008) Differences in mitochondrial function and anti-oxidant systems between regions of human glioma. Cell Physiol Biochem 22:757–768PubMedCrossRef

25.

Jia ZF, Huang Q, Kang CS, Yang WD, Wang GX, Yu SZ, Jiang H, Pu PY (2010) Overexpression of septin 7 suppresses glioma cell growth. J Neurooncol 98:329–340PubMedCrossRef

26.

Darsigny M, Babeu JP, Seidman EG, Gendron FP, Levy E, Carrier J, Perreault N, Boudreau F (2010) Hepatocyte nuclear factor-4alpha promotes gut neoplasia in mice and protects against the production of reactive oxygen species. Cancer Res 70:9423–9433PubMedCrossRef

27.

Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schroter F, Prozorovski T, Lange N, Steffen J, Rieger M et al (2010) Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142:613–624PubMedCrossRef

28.

Ruschak AM, Slassi M, Kay LE, Schimmer AD (2011) Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 103:1007–1017PubMedCrossRef

29.

Tanahashi N, Murakami Y, Minami Y, Shimbara N, Hendil KB, Tanaka K (2000) Hybrid proteasomes. Induction by interferon-gamma and contribution to ATP-dependent proteolysis. J Biol Chem 275:14336–14345PubMedCrossRef

30.

Avril T, Vauleon E, Tanquy-Roger S, Mosser J, Quillien V (2011) Mechanisms of immunomodulation in human glioblastoma. Immunotherapy 3(4Suppl):42–44PubMedCrossRef

31.

Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T, Yang WK (2011) A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci 18:1048–1054PubMedCrossRef

32.

Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203–208PubMedCrossRef

33.

Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8:33–40PubMedCentralPubMedCrossRef

34.

Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297–309PubMedCrossRef

35.

Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938–6947PubMedCrossRef

36.

Gilmore TD (2006) Introduction to NF-kB: players, pathways, perspectives. Oncogene 25:6680–6684PubMedCrossRef

37.

Piaggi S, Raggi C, Corti A, Pitzalis E, Mascherpa MC, Saviozzi M, Pompella A, Casini AF (2010) Glutathione transferase omega 1-1 (GSTO1-1) plays an anti-apoptotic role in cell resistance to cisplatin toxicity. Carcinogenesis 31:804–811PubMedCrossRef

38.

Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ (2000) Activation of the IkB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103:351–361PubMedCrossRef

39.

Masaki M, Ikeda A, Shiraki E, Oka S, Kawasaki T (2003) Mixed lineage kinase LZK and antioxidant protein-1 activate NF-κB synergistically. Eur J Biochem 270:76–83PubMedCrossRef

40.

Takami Y, Nakagami H, Morishita R, Katsuya T, Cui TX, Ichikawa T, Saito Y, Hayashi H, Kikuchi Y, Nishikawa T et al (2007) Ubiquitin carboxyl-terminal hydrolase L1, a novel deubiquitinating enzyme in the vasculature, attenuates NF-kB activation. Arterioscler Thromb Vasc Biol 27:2184–2190PubMedCrossRef

41.

Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM (2001) Raf kinase inhibitor protein interacts with NF-kB-inducing kinase and TAK1 and inhibits NF-kB activation. Mol Cell Biol 21:7207–7217PubMedCentralPubMedCrossRef

42.

Zanotto-Filho A, Braganhol E, Schroder R, de Souza LH, Dalmolin RJ, Pasquali MA, Gelain DP, Battastini AM, Moreira JC (2011) NFkB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 81:412–424PubMedCrossRef

Title: The proteomic response in glioblastoma in young patients
Authors: Ruth F. Deighton
Thierry Le Bihan
Sarah F. Martin
Martin E. Barrios-Llerena
Alice M. J. Gerth
Lorraine E. Kerr
James McCulloch
Ian R. Whittle
Publication date: 01-08-2014
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1474-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The proteomic response in glioblastoma in young patients

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction

The overexpression of Epithelial cell adhesion molecule (EpCAM) in glioma

EMPACT syndrome: limited evidence despite a high-risk cohort

Stereotactic radiosurgery compared with external radiation therapy as a primary treatment in spine metastasis from renal cell carcinoma: a multicenter, matched-pair study

The relationship between working memory and cerebral white matter volume in survivors of childhood brain tumors treated with conformal radiation therapy

Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations